IMAX's Sale Signal Yet to Attract Buyers; Fundamental Thesis Unchanged

What happened

IMAX CEO Rich Gelfond indicated in December that the company was open to a sale, yet no formal suitors have emerged despite record box office and a 50% stock gain over the past year. The lack of interest may reflect valuation, with IMAX trading at 57.8x trailing earnings and 18.8x EV/EBITDA, or strategic concerns about its China exposure, where backlog cancellations have reduced growth visibility. The latest filings show a mixed picture: strong ex-China box office growth but a declining backlog (421 systems vs. 501 a year ago) and weak IMAX China earnings. Our WAIT rating remains intact, as the stock already prices in a strong 2026 slate and requires either a pullback to $37 or proof of share recovery above 3.8% to become attractive. The sale speculation adds optionality but does not alter the fundamental risk/reward at current levels.

Implication

Investors should treat the open-to-sale signal as a potential catalyst but not a reason to buy at current valuation. The absence of buyers suggests that potential acquirers see limited synergies or are deterred by IMAX's premium price and China risks. The core investment case still hinges on premium screen share recovery and backlog quality, which remain uncertain. A sale process could cap downside by attracting interest at a premium, but until a formal offer appears, the stock's fundamentals dominate. We recommend accumulating only near $37 or if the next filings show global share ≥3.8% and backlog stops shrinking.

Thesis delta

The news of potential sale introduces strategic optionality that was not previously factored, but it does not change our fundamental assessment. The lack of buyers may indicate that the market views current valuation as full, reinforcing our WAIT stance. We will monitor for any formal acquisition interest, as a credible bid would likely require a re-rating, but until then the thesis remains unchanged.